NeuroMetrix

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. It focuses on the sale of medical equipment and consumables. Its products include DPNCheck, Quell, and ADVANCE system. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroMetrix reports Q2 revenue decline but shows promise in Quell line

NeuroMetrix faced revenue decline due to DPNCheck product line, offset by strong growth in the Quell product line.
Efficient cost management reflected in a solid gross margin rate of 64% and reduced operating expenses.
The company maintains a healthy financial position with significant working capital and liquid assets.
Strategic review aims to enhance shareholder value and explore new growth avenues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

WOBURN, Mass., July  23, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2020. The Company is a leading developer of neurostimulation-based medical devices that are used to diagnose and treat chronic health conditions.

NeuroMetrix Reports Q2 2020 Financial Results

WOBURN, Mass., July  16, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 second quarter financial results before the opening of the market on Thursday, July 23, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on July 23, 2020 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for Second Quarter 2020 Financial Results Conference Call

WOBURN, Mass., July  09, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced expanded distribution in China for DPNCheck, a fast, accurate and quantitative nerve conduction test for evaluation of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).

NeuroMetrix Reports DPNCheck® Expansion in China

WOBURN, Mass., June  25, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that it has signed a collaboration agreement with Biomedix to comarket DPNCheck for peripheral neuropathy detection within Medicare Advantage and other value-based care markets. NeuroMetrix and Biomedix provide complementary diagnostic tests to physicians and health plans. Within these markets, healthcare providers are focused on detecting and documenting chronic health conditions to determine risk and prevent their costly and debilitating complications.

NeuroMetrix Signs DPNCheck® Collaboration Agreement with Biomedix

WOBURN, Mass., June  10, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has launched a marketing initiative focusing on chronic knee pain.  This effort includes direct-to-consumer digital marketing as well as informing physicians and other health care providers about the use of Quell for their patients with knee pain.

NeuroMetrix to Target Chronic Knee Pain with Quell® 2.0 Wearable Pain Relief Device

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q1 2020 Results - Earnings Call Transcript

WOBURN, Mass., April  16, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology has been selected for use in a large, NIH-funded, randomized, pragmatic clinical trial of TENS for fibromyalgia.  

NeuroMetrix Reports Quell® Technology to be Used in NIH-Funded Trial Evaluating Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS) for Fibromyalgia

WOBURN, Mass., March  11, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today provided an update on its Quell technology commercial strategy and pipeline.

NeuroMetrix Provides Quell® Technology Commercial Strategy and Pipeline Update

WOBURN, Mass., March  05, 2020  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported the recent publication of three additional DPNCheck clinical studies. DPNCheck is a point-of-care test that provides accurate and cost-effective screening, diagnosis and monitoring of peripheral neuropathies such as diabetic peripheral neuropathy (DPN).

NeuroMetrix Reports Clinical Studies Recently Published on DPNCheck®

NeuroMetrix, Inc. (NASDAQ:NURO) Q4 2019 Results Conference Call January 27, 2020 8:00 AM ET

NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q4 2019 Results - Earnings Call Transcript

Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted Basis on November 19, 2019 Shares of Common Stock and Certain Warrants Will Begin Trading on a Split-Adjusted Basis on November 19, 2019

NeuroMetrix Announces One-for-Ten Reverse Split

NeuroMetrix's (NURO) CEO Shai Gozani on Q3 2019 Results - Earnings Call Transcript

WOBURN, Mass., Oct.  17, 2019  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2019.

NeuroMetrix Reports Q3 2019 Financial Results

WOBURN, Mass., Oct.  15, 2019  (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO), a health technology company that develops and commercializes products for the chronic pain and diabetes markets, today announced important updates to its Quell® 2.0 commercial strategy.  This novel wearable device for the symptomatic relief of chronic pain is central to the Company’s vision of helping people reclaim their lives from chronic pain through neuroscience and technology.

NeuroMetrix Announces Updates to Quell 2.0 Commercial Strategy

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q2 2019 Results - Earnings Call Transcript

NeuroMetrix (NURO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate NeuroMetrix (NURO) to Report a Decline in Earnings: What to Look Out for

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q1 2019 Results - Earnings Call Transcript

News for NeuroMetrix Stock (NURO)